New trial
Phase 1 study of NKT5097, a CDK2/CDK4/6 inhibitor for advanced solid tumors.
- Trial ID
- NCT07029399 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 4 Locations
- Published in
- New in Oncology - July 3, 2025
This open-label study evaluates the safety, tolerability, and pharmacokinetics of NKT5097 in adults with advanced/metastatic solid tumors, including breast cancer and CCNE1-amplified cases. The trial features dose escalation and expansion to determine the recommended dose and assess preliminary anti-tumor activity, sponsored by NiKang Therapeutics at multiple U.S. sites.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings